Bone marrow samples from patients with pre-B acute lymphoblastic leukemia (pre-B ALL), either at diagnosis or at relapse, were transplanted intoscid mice to determine whether these freshly obtained leukemic cells could proliferate in vivo and whether there were any differences in their in vivo growth characteristics. Cells from three patients who relapsed within 13 months of diagnosis proliferated rapidly in the murine bone marrow, spleen, and thymus, invaded peripheral organs, and resulted in morbidity and mortality of the animals within 4 to 16 weeks. Cells from two patients who relapsed ERTURBATIONS in the normal human stem cell
P program that lead to leukemic proliferation are difficult to study because both normal and leukemic human stem cells have complex requirements for growth factors and cell-cell interactions that are difficult to reproduce in culture. Furthermore, the difficulties in establishing leukemic cell lines in culture suggest that the cells that do grow in culture have undergone selective processes that may have altered their properties, making them significantly different from the cells taken initially from the patient. Over the past 20 years, most efforts to develop in vivo animal models for human malignancies have focused on the growth of human tumor xenografts in nude mice.' While some human leukemic cells obtained from patients and established cell lines can grow as localized solid tumors or as an ascites in nude mice:-4 growth in these sites does not reflect the normal course of the disease in humans. Recent advances in the transplantation of normal and leukemic human cells into immune-deficient scid and bglnulxid mice provide a unique opportunity to study human hematopoiesis in a mouse modeL5 Normal human myeloid progenitors and lymphoid cells have been detected in the hematopoietic tissues and peripheral circulation of these immune-deficient mice for 6 to 12 months after transplantation of normal human bone marrow (BM),6 peripheral blood leukocytes (PBL),' or fetal liver and thym~s.8,~ Preliminary studies suggest these murine models are also useful for the study of autoimmune dysfunction,"," human immunodeficiency virus (HIV) infecti~n,''.'~ and Epstein-Barr virus (EBV) tran~formation.'~ Pre-B acute lymphoblastic leukemia (pre-B ALL) is the most common form of leukemia in ~hi1dren.I~ Intensive chemotherapy is quite successful for this disease, and currently 60% to 80% of children with ALL achieve prolonged disease-free survival for more than 5 years after diagnosis.I6 However, patients who relapse have poor survival, suggesting the evolution of aggressive variants in some patients. Time to relapse is a fairly reliable prognostic indicator; children with recurrence of ALL within 18 months of diagnosis while still on active chemotherapy have the poorest outcome. " We have previously shown that a human pre-B ALL cell line proliferated and disseminated in scid mice in a manner analogous to the terminal stages of disease in children.I8 Preliminary experiments using a small number of patient samples and a relatively short time of follow-up on the mice indicated that low numbers of leukemic cells could be detected in the BM and spleen of scid mice 4 and 10 weeks after transplantation with BM obtained directly from pre-B ALL patients. We report here that BM samples obtained directly from pre-B ALL patients at relapse with aggressive disease rapidly proliferated and disseminated in scid mice. In contrast, leukemic cells obtained from patients at diagnosis gave low or undetectable proliferation in scid mice followed-up for as long as 9 months. These results suggest there may be a correlation between clinical outcome and the ability of leukemic cells to grow in scid mice and they establish a novel in vivo model to characterize the cellular and molecular mechanisms that govern human leukemic proliferation.
MATERIALS AND METHODS
Leukemic samples. BM and PB from patients were obtained after informed consent and used according to procedures approved by our Human Experimentation Committee. The BM or PB specimens used in this study were obtained from the excess taken for clinical evaluation.
Transplantation of leukemic cells into immune-deficient mice.
The immune-deficient scid mice were bred and maintained in our defined-flora colony (Ontario Cancer Institute) in sterile microisolater cages without any antibiotics. As we previously reported," the health status of the animals is critically important to the success of xenografting human tissues. Before transplantation, the mice were irradiated with 400 cGy from a 137Cs irradiator. No animals die of radiation sickness at this dose. BM cells obtained from the leukemic patients were enriched either by collecting the b u q coat or by Ficoll density gradients, washed in Iscove's modified Dulbec-CO'S medium (IMDM) and injected intravenously (lo7 cells), by tail vein injection into the irradiated scid mice. Animals were killed at the times indicated, usually when they exhibited clinical signs of disease (weight loss, lethargy, ruffled fur); the gross anatomy was surveyed, and tissues were removed for flow cytometry, DNA, and histologic analysis. The animal experiments were approved by the Animal Care Committee of the Ontario Cancer Institute and the Hospital for Sick Children. Flow qtometry analysis. Cell suspensions from the BM, spleen, and thymus were washed in phosphate-buffered saline (PBS) and stained with saturating amounts of monoclonal antibody (MoAb) 44C10 (antihuman CALLA/CD10), '9,20 MoAb 50B4 (antihuman CD44),2'.Z20r MoAb 50D6 (antihuman HLA-DR) and with fluorescein isothiocyanate (F1TC)-goat F (ab')2 antimouse IgG (Tago Labs, Burlingame, CA). These MoAbs were selected because they were reactive with surface antigens on the leukemic cells originally transplanted into mice and were unreactive with murine cells. CD44 is a cell surface glycoprotein widely expressed on human hematopoietic cells and implicated in interactions with endothelial cells. CDlO (CALLA) is neutral endopeptidase (EC 3.4.24.11),** originally described as a marker for ALL and found at the surface of the majority of pre-B ALL (groups I11 and IV). 23 Samples were run on an EPICS Profile Analyzer (Coulter Electronics, Hialeah, FL). Linearity was established with immunobeads and conditions standardized daily by adjusting the voltage in the fluorescence channel such that Immunoclone #3 beads gave a mean log,, fluorescence intensity of 5.25. Thus, all histograms are directly comparable and the relative fluorescence units are linear with respect to log,, fluorescence values. Control MoAbs of the same isotype were run in every experiment and used to set the gates; the percent positive cells in each experiment was determined automatically by reference to the appropriate isotype control and is indicated on each histogram.
DNA was phenol extracted from tissues of transplanted mice using standard techniques. DNA (5 pg) was digested with EcoRI, blotted according to standard protocol, and probed with p17H8, a human a-satellite probe specific for human chromosome 17 sequences.z4 A characteristic 2.7-kb band is indicative of the presence of human sequences. Other, lower molecular weight bands are due to common polymorphisms. The percentage of human DNA present in the mouse tissues was estimated using the human:mouse mixtures indicated: 0% human:100% mouse DNA, 0.1% human:99.9% mouse DNA; 1% human:99% mouse DNA; 10% human:90% mouse DNA. Multiple exposures of the autoradiographs were taken to ensure sensitivity from 0.1% to greater than 10% human cells.
The kidney, liver, lung, spleen, brain, and thymus (if enlarged) from transplanted animals were fixed in 10% formalin. The fixed tissues were paraffin-embedded, and 4 pm sections were cut and stained with hematoxylin and eosin. The stained sections were examined by light microscopy for the presence of leukemic blasts.
DNA analysis.
Histologic analysis.
RESULTS
Charactenstics ofpatients withpre-B ALL at different stages of disease. The eight patients examined in this study were between 2 and 14 years of age and had either a group I11 or group IV pre-B ALL phenotypeU (Table 1) . Three cases R-1, R-2, and R-3 relapsed within 13 months of diagnosis, R-4 and R-5 relapsed within 3 to 4 years, and D-1, D-2, and D- 3 have not yet relapsed (Table 1) . Clinically, it was not possible to establish a durable second remission in any of the early or late relapse patients except for R-5, who is in remission after a BM transplant. Because each of these groups of patients had a different clinical course and outcome of their disease, we wanted to determine whether any of these samples could grow in scid mice and whether there were any differences in their in vivo growth characteristics. Leukemic cells from these patients were transplanted into scid mice using our previously described procedures. Mice (the number of animals was dependent on the excess quantity of cells in the diagnostic aspirates) were irradiated with 400 cGy before intravenous injection of 3 to 10 x lo6
Percoll-enriched BM cells from each of these patients. Generally, mice were killed when they showed clinical signs of disease (weight loss, lethargy, ruffled fur). The presence of leukemic cells in the BM, spleen, and thymus of these animals and the extent of leukemic infiltration into nonhematopoietic tissues were measured by a combination of flow cytometry using markers of leukemic cells (CD10, CD44, HLA-DR, and CD19), DNA analysis using probes specific for the a-satellite sequences on human chromosome 17, and histochemical staining.
Transplantation of leukemic samples from early relapse patients into scid mice. The flow cytometry analysis, using CDlO and CD44, of the BM, spleen, and thymus of representative scid mice that received BM from cases R-1, R-2, and R-3 at relapse, is shown in Fig 1A and the data from all of the animals tested is summarized in Table 1 . High levels of CD44' leukemic cells were found in the BM and thymus of the mice killed 4, 11, and 18 weeks after injection of R-1, R-2, and R-3 cells, respectively; high levels were also seen in the spleen of animals injected with cells from R-1 and R-2, but lower levels were seen for R-3. The level of CD10' was lower than CD44+ on cells for R-1 and R-3, which reflects the phenotype of the original patient samples. It was interesting that the small thymus found in scid mice provided a suitable location for these leukemic cells to proliferate. The presence of leukemic cells in the hematopoietic tissues and in the lung, liver, kidney, and brain of transplanted mice was determined by DNA analysis using human-specific probes. Comparison of the intensity of the 2.7-kb EcoRI band, characteristic of the a-satellite sequences on human chromosome 17, between the known human:mouse control mixtures and the scid samples showed heavy infiltrates of human cells in all of the tissues tested, indicative of aggressive, widely disseminated leukemia ( Fig 1B; Table 1 ). Although the BM from R-3 took longer (18 weeks) than R-1(4 weeks) and R-2 (1 1 weeks) to grow in the mice, it should be noted that the BM sample had been frozen and the actual number of viable cells injected into mice was 3 x lo6.
To determine whether the human leukemic cells could be passaged in scid mice and whether their growth characteristics would change, BM (lo6 cells) from R-1 was serially 
weeks (R-l), 11 weeks (R-2), or 18 weeks (R-3). (B)
DNA analysis of the BM, spleen (SP), lung (LU), liver (LIV), kidney (KID), brain (BR), or thymus (THY) of the same scid mice shown above. In addition, DNA was analyzed from R-1 mice 2, 4, and 5 weeks after injection. DNA (5 pg) was digested with EcoRI, blotted according t o standard protocol, and probed with p17H8, a human a-satellite probe specific for human chromosome 17 sequences. The percentage of human DNA present in the mouse tissues was estimated using the human:mouse mixtures indicated: 0% human:100% mouse DNA; 0.1% human:99.9% mouse DNA; 1 YO human:99% mouse DNA; 10% human:90% mouse DNA. The autoradiograph for samples from mice transplanted with R-1 cells and the adjacent controls was exposed for 8 hours while the other samples and adjacent controls were exposed for 4 hours after using probes with different specific activities.
passaged in scid mice every 6 weeks when the animals showed clinical signs of disease. We passaged the cells eight times with no noticeable changes in the growth rate, extent, or pattern of leukemic infiltration between passages 2 and 8, indicating that in vivo passage was not selecting for faster growing variants. Kinetic studies at the second passage showed the rapid proliferation of cells initially in the BM with heavy infiltrates detected as early as 2 weeks (Fig IB) . Dissemination of leukemic cells occurred within the next 2 weeks into spleen, kidney, lung, liver, thymus, and, to a lesser extent, brain. At 5 weeks, each of these organs was heavily infiltrated and the animals died by week 6.
Histologic examination of the tissues obtained from the mice engrafted with each of the relapse samples was consistent with aggressive leukemic proliferation (Fig 2;  Table 1 ). Figure 2 shows a representative mouse engrafted with cells from patient R-I. The kidneys showed extensive leukemic cell infiltration of the interstitial regions under the capsule and in the perirenal fat. In the liver, leukemic cells extensively infiltrated into the periportal region and around the central vein extending into the hepatic sinusoids. The normal kidney and liver morphology was obliterated by the presence of blasts in some areas. Leukemic cells also infiltrated the cerebral cortex within the meningeal For personal use only. on November 11, 2017. by guest www.bloodjournal.org From space. The lungs also showed heavy infiltrates (data not shown).
In addition to transplantation into scid mice, the BM samples from these relapse patients were also grown in in vitro culture using previously described methods." Cell lines were established within 8 to 10weeks (Table 1) . The in vitro and in vivo growth characteristics of a line derived from R-1 will be published elsewhere.2h
Transplantation of leukemic samples from late relapse patients into scid mice. BM samples obtained at relapse from cases R-4 and R-5, who both relapsed 3 to 4 years after diagnosis, grew more slowly in scid mice than the early relapse samples (Fig 3A and B ; Table 1 ). Scid mice injected with cells from R-4 were killed at 4, 8, and 27 weeks. We previously showed that the BM from scid mice transplanted with R-4 cells contained 1% to 10% leukemic cells at 4 and 8 weeks (patient 2 in Kamel-Reid et al'"). Two additional animals were followed-up for 27 weeks and killed when they began to show signs of disease. One of the animals (not shown) had a thymoma of mouse origin and no human cells were detected in any tissues by DNA analysis (not shown). The BM of the other animal (R-4-1") contained 78% CDlO' and the spleen 6% HLA-DR+ leukemic cells ( Fig  3A) . DNA analysis on the tissues of this mouse showed a variable degree of infiltration, with the lung and liver showing the highest level of infiltration (5% to 10%) ( Fig  3B) . The low number of BM cells precluded DNA analysis. BM passaged from this mouse into another scid mouse (R-4-2") again took 30 weeks to reach similar levels of infiltration, indicating that in vivo passage was not selecting for faster growing variants (Fig 3A and B) .
Mice injected with BM from case R-5, who relapsed 42 months after diagnosis, were killed 8 months later; the level of engraftment, as determined by flow cytometry, was low, with 6% leukemic cells detected in the BM (Fig 3A) . DNA analysis substantiated this level of engraftment in the BM; small infiltrates of human cells were also detected in the kidney, liver, lung, brain, and thymus, while no human DNA was detected in the spleen. Histologic examination of tissues from these mice confirmed the presence of small foci of leukemic cells (not shown). These data indicate that R-4 cells were more aggressive in their growth pattern in scid mice than R-5 cells. However, it is also possible that the lower level of proliferation was due to the fact that the BM sample from R-5 contained fewer leukemic blasts, resulting in less leukemic cells being transplanted into scid mice ( Table 1) . The clinical outcome for R-5 and R-4 was also different. It was possible to establish a second remission in R-5; the patient had a BM transplant 15 months ago and is still disease free. A durable second remission could not be established in R-4.
Transplantation of leukemic samplesfrom patients at diagnosis into scid mice. In contrast to the results obtained with cells from patients at relapse, the BM samples taken from patients at diagnosis did not proliferate or else proliferated to low levels after injection into scid mice (Table 1) . Flow cytometry analysis showed the presence of 5% human leukemic cells in the BM of scid mice 5 months after engraftment with BM from case D-1 (Fig 4A) . DNA and histologic analyses indicated that other tissues were either uninvolved or infiltrated at a low level (1%) (Fig 4B;  Table 1 ). We have previously shown low levels of human cells in scid mice 4 to 10 weeks after transplantation with diagnosis samples from D-2 and D-3 (patient 1 and 3 in Kamel-Reid et all'); however, no human cells could be detected by flow cytometry, DNA, and histochemical analysis of additional mice from these groups after longer periods of observation (up to 9 months) ( Table 1) . None of the patients whose diagnostic sample failed to grow to a significant extent in scid mice have relapsed to date.
DISCUSSION
The experiments described here establish that leukemic cells from patients with poor prognosis, ie, those who 1 . idea is strengthened by experiments that showed that some factor-dependent pre-B ALL cells could be supported on adherent layers of murine stromal ceIIs." There was an absolute requirement for cell-cell contact because the leukemic cells did not proliferate in stromal cell-conditioned medium. We have similarly found that the human growth factor-dependent myeloid cell line Mo7E can proliferate in immune-deficient mice as well as on murine embryo fibroblasts (unpublished).
HLA-DR (BM) 7%
Cell lines were established from the patients with aggressive clinical disease (R-2, R-1, and R-3) using previously reported techniques" including incubation in various combinations of recombinant growth factors as well as autologous conditioned media prepared from the leukemic cells themselves (Table 1) . However, no cell lines could be established from any other patient samples, nor from the heavily infiltrated tissues of scid mice transplanted with R-4 cells. Despite the slow growth of R-4 in primary scid mice, they could be passaged into secondary scid recipients. Therefore, the proliferation of human leukemic cells in vivo D-1 5mo provides a valuable method to expand and preserve Ieukemic cells that cannot be established in culture.
After an initial response to chemotherapy, approximately 20% of children with pre-B ALL have recurrence of leukemia that is often drug-resistant and difficult to treat effectively; these children have a much poorer prognosis than those with newly diagnosed leukemia."' The growth of drug-resistant relapse leukemic samples in scid mice provides a model to test treatment modalities directed against the drug-resistant cells that are probably more relevant than in vitro drug studies. In addition, several approaches have been developed to detect small numbers of residual leukemic cells either as prognostic tools or to test the efficacy of BM purging techniques. These approaches include clonogenic assays for the leukemic stem cell2x or the molecular detection of specific chromosomal abnormalities by polymerase chain reaction (PCR)."' The advantage of the scid model over molecular detection methods such as PCR is that it provides a biologic assay for residual leukemia by directly testing the ability of the cells to grow
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From and disseminate. The experiments in this report show that the transplantation of between 3 and 10 x 106 leukemic cells from relapse patients into scid mice leads to leukemic proliferation. A large limiting dilution experiment was performed using a cell line (G2) derived from patient R-1. We have found that as few as 100 G2 cells were sufficient to cause leukemic proliferation in scid mice? suggesting that the scid model can support the growth of low numbers of aggressive leukemic cells. It will now be interesting to follow-up a larger group of patients, from diagnosis to relapse, to determine whether low numbers of residual leukemic cells in patients who relapse can be detected in scid mice. The low frequency of relapse cases in pre-B ALL will make it necessary initially to enroll a large number of patients and observe them for a long period of time. Our finding that frozen cells can be transplanted into mice should simplify the design of such a large study.
One of the fundamental problems in cancer biology is the identification of the genetic alterations that lead to leukemic transformation and progression. The difference in in vivo growth characteristics between the relapse and diagnosis groups cannot be ascribed to the number of leukemic blasts present in the BM samples because they contained equivalent numbers of blasts (Table 1) . Rather, the scid model provides an environment in which the intrinsic biologic properties of the leukemic cell that give them aggressive growth properties in both the patient and in scid mice can be manifested. As a result, the scid-leukemia model becomes a biologic assay for the genetic factors that lead to leukemic progression. By combining this leukemia model with high-efficiency gene transfer technique^,^^." it will be possible to test genetic factors such as oncogenes and tumor suppressor genes for their role in the transformation and progression of human leukemia.
